Genetic determinants ofEGFR-Driven Lung Cancer Growth and Therapeutic ResponseIn Vivo
Osimertinib
DOI:
10.1101/2020.04.13.036921
Publication Date:
2020-04-14T01:52:12Z
AUTHORS (20)
ABSTRACT
Abstract Cancer genome sequencing has uncovered substantial complexity in the mutational landscape of tumors. Given this complexity, experimental approaches are necessary to establish impact combinations genetic alterations on tumor biology and uncover genotype-dependent effects drug sensitivity. In lung adenocarcinoma, EGFR mutations co-occur with many putative suppressor gene alterations, however extent which these contribute growth their response therapy vivo not been explored experimentally. By integrating a novel mouse model oncogenic -driven Trp53 -deficient adenocarcinoma multiplexed CRISPR–Cas9-mediated editing barcode sequencing, we quantified inactivation ten genes. Inactivation Apc , Rb1 or Rbm10 most strongly promoted growth. Unexpectedly, Lkb1 Setd2 – strongest drivers an Kras reduced These results consistent relative frequency human EGFR- KRAS adenocarcinomas. Furthermore, Keap1 reduces sensitivity tumors inhibitor osimertinib. Importantly, EGFR/TP53 mutant adenocarcinomas, KEAP1 pathway correlated decreased time tyrosine kinase treatment. Our study highlights how can have dramatically different biological consequences depending context that fitness shift upon
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (82)
CITATIONS (3)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....